Cocrystal Pharma, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2020 - Q4(Oct 20 · Nov 20 · Dec 20)
Total Assets
$10M
↓-27.8% -$4Mvs FY2024
Total Liabilities
$3M
↓-14.0% -$552Kvs FY2024
Equity
$6M
↓-33.5% -$3Mvs FY2024
Cash
$7M
↓-28.8% -$3Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $10M | $13M |
| Current Assets | $8M | $12M |
| Cash | $7M | $10M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $1M | $2M |
| Non-Current Assets | $2M | $2M |
| PPE | $93K | $153K |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $1M | $2M |
| Total Liab+Eq | $10M | $13M |
| Current Liab. | $2M | $2M |
| Accounts Payable | $890K | $2M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $1M | $886K |
| Non-Current Liab. | $1M | $2M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $1M | $2M |
| Equity | $6M | $10M |
| Retained Earnings | $342M | $333M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · COCP · Comparing FY2025 vs FY2024